Literature DB >> 29199707

Evolving epidemiology of lung cancer in India: Reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key.

H Kaur1, I S Sehgal1, A Bal2, N Gupta3, D Behera1, A Das2, N Singh1.   

Abstract

BACKGROUND: Adenocarcinoma is the most prevalent histological type of lung cancer (LC) in developed countries while squamous cell carcinoma (SqCC) has so far been the most common type at our center. Herein, we report our continued assessment of the epidemiological trend of LC aimed at determining any change in the histological distribution.
METHODS: Retrospective analysis involving all consecutive newly diagnosed LC patients over a 4-year period (March 2011-February 2015). Demographic characteristics, histology, and staging data for current data set were compared with our previously published data (2008-2011). As before, smoking index (SI) was used to group patients as never (SI = 0), light (SI = 1-100), moderate (SI = 101-300), and heavy (SI ≥301) smokers.
RESULTS: Majority of 1301 patients had advanced disease (Stages IIIB = 30.1%; IV = 53.3%), were males (82.3%) and current/ex-smokers (76.9%). Adenocarcinoma and SqCC (36.4% each) were equally prevalent. As compared to our previous study, adenocarcinoma increased (36.4% vs. 27.5%) and nonsmall cell lung cancer-not otherwise specified (NSCLC-NOS) decreased (5.1% vs. 10.9%) significantly (P < 0.001). The current study had more heavy smokers (68.3% vs. 61.1%; P = 0.013) and median SI was also higher (500 vs. 400; P = 0.001). Among SI-based groups, significant differences were observed for age, gender, body mass index, histology, TNM stage, and metastatic disease distribution.
CONCLUSION: Reduction in NSCLC-NOS has led to adenocarcinoma and SqCC being equally prevalent at our center in North India despite an increase in heavy smokers. Accurate histological NSCLC subtyping is necessary for optimal epidemiological assessment.

Entities:  

Mesh:

Year:  2017        PMID: 29199707     DOI: 10.4103/ijc.IJC_597_16

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  8 in total

1.  Utility of the revised Edmonton Symptom Assessment System (ESAS-r) and the Patient-Reported Functional Status (PRFS) in lung cancer patients.

Authors:  M N Yogananda; Valliappan Muthu; Kuruswamy Thurai Prasad; Adarsh Kohli; Digambar Behera; Navneet Singh
Journal:  Support Care Cancer       Date:  2017-10-12       Impact factor: 3.603

2.  Expression of engrailed homeobox 2 regulates the proliferation, migration and invasion of non-small cell lung cancer cells.

Authors:  Xiangxiao Lin; Xincun Liu; Cunqi Gong
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

3.  Clinical profile of lung cancer in North India: A 10-year analysis of 1862 patients from a tertiary care center.

Authors:  Anant Mohan; Avneet Garg; Aditi Gupta; Satyaranjan Sahu; Chandrashekhar Choudhari; Vishal Vashistha; Ashraf Ansari; Rambha Pandey; Ashu Seith Bhalla; Karan Madan; Vijay Hadda; Hariharan Iyer; Deepali Jain; Rakesh Kumar; Saurabh Mittal; Pawan Tiwari; Ravindra M Pandey; Randeep Guleria
Journal:  Lung India       Date:  2020 May-Jun

4.  Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients.

Authors:  Kuruswamy Thurai Prasad; Harpreet Kaur; Valliappan Muthu; Ashutosh Nath Aggarwal; Digambar Behera; Navneet Singh
Journal:  World J Clin Oncol       Date:  2018-11-10

5.  Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma.

Authors:  Dongchang Wang; Yan Gao; Yu Zhang; Lifei Wang; Gang Chen
Journal:  Biosci Rep       Date:  2019-06-25       Impact factor: 3.840

6.  Challenges in the Management of Lung Cancer: Real-World Experience from a Tertiary Center in South India.

Authors:  Vishnu Gopal; Biswajit Dubashi; Smita Kayal; Prasanth Penumadu; Manju Rajaram; Gunaseelan Karunanithi; Subathra Adithan; Pampa Ch Toi; Prasanth Ganesan
Journal:  South Asian J Cancer       Date:  2021-12-20

7.  A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution.

Authors:  Mohana Roy; Amanjit Bal; Nalini Gupta; Kuruswamy T Prasad; Heather A Wakelee; Navneet Singh
Journal:  Lung India       Date:  2022 Jul-Aug

8.  Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?

Authors:  Navneet Singh
Journal:  Lung India       Date:  2017 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.